New Local TV Ad Campaign To Educate Memphis Women About Cervical Cancer Prevention and HPV Testing – Through a new advertising campaign being launched in US, local women will soon learn more about cervical cancer screening and prevention.
Merck & Co., Inc. Receives Complete Response Letter from the Food and Drug Administration for Use of GARDASIL? in Women Ages 27 through 45 – Merck & Co., Inc. announced that the U.S. Food and Drug Administration has issued a second complete response letter regarding the supplemental biologics license application (sBLA) for the use of GARDASIL [Human Papillomavirus Quadrivalent (Types 6, 11, 16, 18) Vaccine, Recombinant] in women ages 27 though 45.
Allergy and immunology consultant Liew Woei Kang and colleagues found that true hypersensitivity to the quadrivalent human papillomavirus vaccine was uncommon, and most girls in Australian schools tolerated subsequent doses. – Hypersensitivity reactions to the quadrivalent HPV vaccine (4vHPV, Gardasil) are uncommon and most schoolgirls can tolerate subsequent doses, finds the first evaluation of the quadrivalent HPV vaccine published on bmj.com.
Researchers are developing a new screening MRI imaging technique for cervical cancer that would be more effective at spotting tumours early. – Using high-resolution magnetic resonance imaging (MRI) with a special vaginal coil, a technique to measure the movement of water within tissue, researchers may be able to identify cervical cancer in its early stages, according to a new study being published in the November issue of Radiology.
Gardasil vaccine to prevent cervical cancer in India, launched by MSD Pharmaceuticals – the local affiliate of Merck. – MSD Pharmaceuticals India announced the launch of GARDASIL Vaccine, India’s first vaccine to help prevent Cervical Cancer caused by the HPV.
First published study of new HPV test – QIAGEN’s careHPV test for developing countries shows high accuracy in predicting cervical disease, cervical cancer. – A new HPV test developed by QIAGEN specifically for use in regions of the world with scarce resources is “substantially” more accurate in identifying women with cervical disease than the current methods (Pap testing and visual inspection) in these countries.
Jo’s Trust cervical cancer charity welcomes Department of Health’s announcement about HPV vaccine Cervarix. – The UK’s leading cervical cancer charity, Jo’s Trust, has welcomed the UK’s Department of Health’s announcement that the HPV vaccine, Cervarix will be used in the national immunisation programme for 12/13 year olds starting in September, 2008.
New research into the causes of cervical cancer appears to lend weight to the promise of a potential early detection method that could help prevent the disease. – Persistent infection with human papillomavirus (HPV) could be a useful clinical marker for increased risk of cervical cancer, the second most common cancer in women worldwide, revealed by researchers from the University of North Carolina at Chapel Hill.
U.S. mothers report they are less likely to vaccinate daughters under age 13 against human papillomavirus virus (HPV), even though the vaccine is recommended for girls at age 11 and 12. – U.S. mothers report they are less likely to vaccinate daughters under age 13 against human papillomavirus virus (HPV), even though the vaccine is recommended for girls at age 11 and 12, it’s incumbent upon the healthcare community to work to improve mom’s acceptance of the vaccination for younger daughters, say researchers at Cincinnati Children’s Hospital Medical Center who conducted the study.
In testing GARDASIL reduced abnormal Pap test results by 43 percent compared to women not given the vaccine, according new research. The findings show the approved anti-HPV agent appears to prevent the development of cell changes that lead to cervical disease. – A significant drop in abnormal Pap test results happened after girls and women were given Gardasil vaccine to prevent cervical cancer, according to a researcher at the University of Alabama at Birmingham (UAB).